XTX Topco Ltd Sells 23,444 Shares of Moderna, Inc. (NASDAQ:MRNA)

XTX Topco Ltd lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 83.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,812 shares of the company's stock after selling 23,444 shares during the period. XTX Topco Ltd's holdings in Moderna were worth $200,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of MRNA. Lansdowne Partners UK LLP bought a new position in shares of Moderna during the 4th quarter worth approximately $1,455,000. Townsquare Capital LLC boosted its stake in Moderna by 14.2% during the fourth quarter. Townsquare Capital LLC now owns 6,040 shares of the company's stock worth $251,000 after acquiring an additional 752 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new stake in Moderna in the fourth quarter worth $686,000. Treasurer of the State of North Carolina increased its stake in Moderna by 3.8% in the fourth quarter. Treasurer of the State of North Carolina now owns 206,884 shares of the company's stock valued at $8,602,000 after purchasing an additional 7,490 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Moderna during the fourth quarter valued at about $8,493,000. Institutional investors own 75.33% of the company's stock.

Moderna Stock Up 2.6 %

NASDAQ MRNA traded up $0.72 during trading hours on Wednesday, reaching $28.54. 7,706,307 shares of the company were exchanged, compared to its average volume of 7,369,266. The stock has a market capitalization of $11.03 billion, a P/E ratio of -3.08 and a beta of 2.23. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47. The business's 50 day simple moving average is $29.91 and its 200-day simple moving average is $38.08.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research reports. Royal Bank of Canada restated a "sector perform" rating and issued a $40.00 target price on shares of Moderna in a research note on Tuesday, February 18th. William Blair restated a "market perform" rating on shares of Moderna in a report on Thursday, April 17th. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and cut their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. UBS Group decreased their price target on shares of Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a research note on Wednesday, February 19th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Friday, March 21st. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of "Hold" and a consensus target price of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.